Current location - Health Preservation Learning Network - Health preserving class - Development prospect of Wuhan Jiushengtang Bioengineering Co., Ltd.
Development prospect of Wuhan Jiushengtang Bioengineering Co., Ltd.
In 20 12, there was a "polypeptide plate fever" in China stock market, and the company's polypeptide products were the initiator of this "polypeptide fever". Soros, the American capital operation tycoon, once intended to hold hands with the company, and dozens of domestic venture capital institutions also intended to "grab the beach" the company. The former leader of the former Sanjiu Group has twice set out to turn the company into "Sanjiu Medicine" or an overseas listed company. Because the company leaders disagreed, the company's "theory and practice of enzymatic peptides" became the direction of the world's polypeptide field. The popularity of the company's enzyme and polypeptide projects and technologies is the main factor for tens of thousands of domestic enterprises and units to enter this industry. Especially in Wuhan, where the company is located, dozens of enterprises follow and imitate their technologies and products, but none of them have been approved, and the infringement is very serious.

At present, the company has built a 4,500-square-meter workshop in the Biomedical Park of Wuhan Donghu High-tech Development Zone, and is undergoing GMP transformation. The design and production capacity of the plant is 6.5438 million boxes of polypeptide oral liquid products every year, and it will also produce polypeptide raw materials, polypeptide drinks, polypeptide tablets and capsules, and polypeptide cosmetics, with an annual production capacity of 2 billion yuan. The company also invested and registered Wuhan Enzyme Polypeptide Biotechnology Co., Ltd. in Wuhan Donghu High-tech Development Zone; Hubei Pueraria Peptide Beverage Biotechnology Co., Ltd. was established in Macheng, an old revolutionary area in Hubei, with a daily output of10.2 million bottles. Recently, the company has completed the counseling for the listing of the New Third Board, and plans to officially list the New Third Board before the end of 20 13.

The company's business objectives are: to enlarge and strengthen the enzymatic polypeptide industry, take peptides as the new basic nutrition for all mankind, strengthen China people with peptides, and make China people become "Oriental strongmen" in the field of human health! .